EVAX — Evaxion A/S

—
Nasdaq · Health Care · Biotechnology · CIK 1828253 · Denmark
Last close
$2.78
Market Cap
$25.08M
52W High
$6.92
52W Low
$2.65
ADV30
108,697
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -3,846,000 -3,729,000 19,380,000 14,000,000 9,849,000
Mar 2026 0 — -3,819,000 -3,629,000 23,642,000 18,440,000 10,435,000
Dec 2025 0 — -4,052,000 -5,918,000 28,408,000 23,234,000 11,369,000
Sep 2025 7,492,000 — 3,023,000 4,618,000 29,737,000 10,572,000 13,138,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-133,603,000
Inventory
—
Receivables
$1,858,000
ST Investments
—
EBIT TTM
$-9,858,000
Pretax Income TTM
$-9,599,000
Interest Exp TTM
$-259,000
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$7,491,000
EBITDA
$-8,326,000
Free Cash Flow
$-5,487,625
Enterprise Value
$19,209,872
Total Cash
$14,000,000
Total Debt
$7,105,000
Shares Out
9,021,483
Trailing EPS
$-0.50
Book Value
$1.14
ROE
-109.9%
ROA
-26.0%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 7,528,000 -9,234,000 -7,707,000 28,408,000 11,369,000 17,039,000 -6,625,000
Dec 2024 3,344,000 -14,732,000 -10,567,000 12,485,000 14,137,000 -1,652,000 -12,940,000
Dec 2023 73,000 -22,197,000 -22,125,000 12,889,000 17,618,000 -4,729,000 -17,691,000
Dec 2022 0 -25,264,000 -23,169,000 22,025,000 13,722,000 8,303,000 -25,774,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.01

Peers — same industry

TickerNameMarket CapLastDaily %
LONA LeonaBio, Inc. $26.00M $2.76 —
MGX Metagenomi Therapeutics, Inc. $23.86M $0.63 —
PTHS Pelthos Therapeutics Inc. $26.89M $6.84 —
ZIVO Zivo Bioscience, Inc. $23.18M $5.50 —
SAEN Genenta Science S.p.A. $27.82M $0.58 —

News headlines (Yahoo Finance, 1h cache)

Evaxion to announce strategy and business update and third quarter 2026 financial results on November 19, 2026
2026-11-18 13:30 · Yahoo
Evaxion announce 2027 financial calendar
2026-11-12 13:00 · Yahoo
Evaxion files amendment to registration statement related to 2025 EIB debt settlement agreement
2026-11-09 13:00 · Yahoo
New phase 2 data highlight the strength of the immune response induced by personalized cancer vaccine EVX-01
2026-11-06 16:00 · Yahoo
Evaxion will present new target validation data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia at ASH 2026 Meeting
2026-11-04 14:00 · Yahoo
Evaxion to present broad biomarker data from phase 2 trial with personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
2026-11-03 14:00 · Yahoo
Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution
2026-10-30 08:00 · Yahoo
Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
2026-10-23 06:00 · Yahoo
European Equities Traded in the US as American Depositary Receipts Advance in Tuesday Trading
2026-10-20 15:10 · Yahoo
European Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Trading
2026-11-16 16:21 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.